Investing
Brean Murray Comments on Dendreon (DNDN) Following Friday's Run-Up
Published:
Last Updated:
Brean Murray comments on Dendreon (Nasdaq: DNDN) this morning, following Friday’s 38% run-up, which they said was related to competitor’s call with a physician in the field and word Provenge Phase 3 trial results being slated for potential presentation on April 28 at the American Urological Association annual meeting. Brean Murray said neither of these changes anything fundamental about the trial outcome.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.